BDTX
Black Diamond TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Positive preliminary silevertinib efficacy, meaningful CNS activity, a potential FDA pivotal-path discussion, and runway into 2H 2028 could support rerating if clinical durability and regulatory positioning hold.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.9.
What can break
FDA feedback could delay, narrow, or change the pivotal development plan.
Momentum
77
Value
62
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.85 · Bull $2.80 · Bear $0.95
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.86
Why
Momentum77 · Δ7d -15.6
Value62 · Δ7d +0.9
Sentiment50 · Δ7d +4.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
77
26% active weight
Current posture
7d trendImproving
Δ7d
-15.6
Δ21d
-15.6
Value
62
39% active weight
Current posture
7d trendFlat
Δ7d
+0.9
Δ21d
+17.3
Sentiment
50
34% active weight
Current posture
7d trendSoftening
Δ7d
+4.2
Δ21d
+4.2
Why this grade
Composite grade A. Momentum 77.0 / Value 61.6 / Sentiment 49.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$102.57M
Beta
3.37
Shares Out
57.3M
P/E (TTM)
7.1
P/S (TTM)
2.09
P/FCF (TTM)
6.86
Rev YoY
-100.0%
EPS YoY
-116.1%
Gross Margin
+99.5%
Op Margin
+16.9%
Net Debt
-$109.87M
Current Ratio
8.46
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology